Aktieanalys

Egetis: Patients on Emcitate associated with survival benefits - Redeye

Redeye Publicerad: 21 Aug 10:33

Redeye is optimistic about today’s news from Egetis Therapeutics that patients on Emcitate are associated with survival benefits compared to patients not on treatment. According to the release, Emcitate patients are “associated with an approximately three times lower risk of mortality compared to MCT8 deficiency patients not treated with tiratricol”, which clearly indicates a clinical relevance to treat chronic thyrotoxicosis in all patients. We will discuss these results more in relation to the Q2 report tomorrow.

Länk till analysen i sin helhet: https://www.redeye.se/research/1032010/egetis-patients-on-emcitate-associated-with-survival-benefits?utm_source=finwire&utm_medium=RSS

Nyheter om Egetis Therapeutics

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!